Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Lactobacillus reuteri DSM 17938 and Reduced Hospital Stay

Doses used in studies

CFU/day: 100 million–400 million (median 250 million, IQR 175 million–325 million) — 2 studies

Time to effect

Median: 5 days · IQR 5 days–5 days · Range 5 days–5 days — Reported in 1 of 2 studies

Safety in these studies

Overall tolerabilityReported
No adverse effects were reported.
from: Lactobacillus reuteri DSM 17938 effectively reduces the duration of acute diarrhoea in hos
Overall tolerabilityReported
No adverse events were recorded.
from: Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with ac

2 of 2 papers

Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhoea--a double-blind study.
- 2012-06-11
- RCT
- Alimentary pharmacology & therapeutics 36(4)
- - R Francavilla
  - E Lionetti
  - S Castellaneta
  - F Ciruzzi
  - F Indrio
  - A Masciale
  - C Fontana
  - M M La Rosa
  - L Cavallo
  - A Francavilla
- PubMed: 22680836
- DOI: 10.1111/j.1365-2036.2012.05180.x
4 Insights on
- Reduced Hospital Stay
- High evidence
- Rigorous Journal
- Clinical
There was not a significant difference in hospital stay between the groups.
Effect
Neutral
Effect size
Small
Significant
No
Dose
4 × 10^8 colony-forming units/day
Lactobacillus reuteri DSM 17938 effectively reduces the duration of acute diarrhoea in hospitalised children.
- 2014-03-24
- RCT · n = 64
- Acta paediatrica (Oslo, Norway : 1992) 103(7)
- - Ener Cagri Dinleyici
  - Yvan Vandenplas
- PubMed: 24579935
- DOI: 10.1111/apa.12617
2 Insights on
- Reduced Hospital Stay
- High evidence
- Clinical
Lactobacillus reuteri reduced mean hospital stays (4.31 ± 1.3 days versus 5.46 ± 1.77 days, p < 0.001).
Effect
Beneficial
Effect size
Moderate
Significant
Yes
Dose
1 × 10^8 CFU for 5 days